Everything below concerns thymalfasin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-02. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Reconstituted before use |
| Typical storage | 2-8 °C, protected from light | Applies to the powder |
| Reconstitution solvent | Sterile water or saline | Follow product labeling |
| Solution stability | Shorter than the powder | Refrigerate and use promptly |
| Primary purity method | Reversed-phase HPLC | Detects related substances |
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
== Development of first generation ACE inhibitors == The development of the nonapeptide teprotide (Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro), which was originally isolated from the venom of the Brazilian pit viper Bothrops jararaca, greatly clarified the importance of ACE in hypertension. However, its lack of oral activity limited its therapeutic utility. L-benzylsuccinic acid (2(R)-benzyl-3-carboxypropionic acid) was described to be the most potent inhibitor of carboxypeptidase A in the early 1980s. The authors referred to it as a by-product analog and it was proposed to bind to the active site of carboxypeptidase A via succinyl carboxyl group and a carbonyl group. Their findings established that L-benzylsuccinic acid is bound at a single locus at the active site of carboxypeptidase A. The authors discussed but dismissed the suggestion that the carboxylate function might bind to the catalytically functional zinc ion present at the active site. Later however this was found to be the case.
== History == In the 1940s Craig invented the first apparatus to conduct countercurrent partitioning; he called this the countercurrent distribution Craig apparatus. The apparatus consists of a series of glass tubes that are designed and arranged such that the lighter liquid phase is transferred from one tube to the next. The next major milestone was droplet countercurrent chromatography (DCCC). It uses only gravity to move the mobile phase through the stationary phase which is held in long vertical tubes connected in series. The modern era of CCC began with the development of the planetary centrifuge by Ito which was first introduced in 1966 as a closed helical tube which was rotated on a "planetary" axis as is turned on a "sun" axis. Centrifugal partition chromatography was introduced in Japan in 1982; the first instrument was built at Sanki Eng. Ltd. in Kyoto. The first instrument consisted of twelve cartridges arranged around the rotor of a centrifuge; the inner volume of each cartridge was about 15 mL for 50 channels. In 1999 Kromaton developed the first FCPC with radial cells. During cell development, the Z cell was completed in 2005 and the twin cell in 2009. In 2017 RotaChrom designed its top performing CPC cells through computed fluid dynamic simulation software by László Németh and László Lorántfy. After thousands of simulations, this tool revealed the drawbacks of conventional CPC cell designs and highlighted the unparallel load capacity and scalable cell design of RotaChrom. Both researchers left RotaChrom in Sept 1 2019.
== Archaeological investigation == The site was discovered in 1982 when a team led by Francis Pryor carried out a survey of dykes in the area funded by English Heritage. In 1992 Pryor told National Geographic that he "stumbled – literally – upon' Flag Fen 'when he tripped on a piece of wood lying in the bottom of a drainage ditch." Excavation commenced in the Summer of 1984 and by 1990 had revealed vertical and horizontal timbers, animal bones, a bronze dagger and other metal items and fragments, flint implements and 400 potsherds. Further finds included items imported from continental Europe and the oldest surviving wooden wheel found in England, dating from 1300 BC. In 2012 DigVentures ran the world's first crowdfunded excavation, raising £30,000 to enable a three-week excavation at Flag Fen. The site had experienced a 50% decline in visitors since the large-scale English Heritage-funded excavations had finished in 1995. The project's remit was to help revitalise the heritage attraction whilst providing detailed scientific information on the preservation of the waterlogged timbers. The project involved around 250 members of the public from 11 countries, supported by a specialist team including partners from the British Museum, Durham University, Birmingham University, York Archaeological Trust, University College London and English Heritage to assist in the scientific investigations. 130 members of public received hands-on training in archaeological techniques on site and visitor numbers increased by 29% from the previous year.
Sources: en.wikipedia.org
== Platforms == Current nanoparticle drug delivery systems can be cataloged based on their platform composition into several groups: polymeric nanoparticles, inorganic nanoparticles, viral nanoparticles, lipid-based nanoparticles, and nanoparticle albumin-bound (nab) technology. Each family has its unique characteristics.
== Medicines == Treatments based on monoclonal antibodies have been produced related to CGRP or CGRP receptors. They have been shown to be effective in patients who experience migraine headaches, both with and without aura, and both episodic and chronic cluster headache. These are the first class of preventive medications originally designed and approved for people with migraine. Due to the nature of the monoclonal antibodies, they must be administered parenterally, preferably by injection. The first CGRP related medication approved by the FDA is called erenumab (trade name Aimovig), produced by pharmaceutical company Amgen and Novartis. It interacts with the CGRP receptor. It is injected once monthly with a dose of 70 or 140 mg. Few adverse effects were reported (most related to injection site reactions) and patients had a significant reduction in migraines. The second approved by the FDA is fremanezumab (trade name Ajovy), produced by the Teva Pharmaceuticals company. It interacts with the CGRP protein, whose expression is related to migraine attacks. It may be administered monthly or every three months, giving options for users. Trials have shown a reduction of greater than 50% of migraine days for those who responded. There were few significant side effects during trials, most related to injection site reactions. The third CGRP medication approved by the FDA is galcanezumab (trade name Emgality), produced by the Eli Lilly and Company. It interacts with the CGRP protein, whose expression is related to migraine attacks.
In April 2022, Collins embarked on her first live theatre tour, titled The GC's Big Night Out. Performing in venues across the UK, the seven-date tour was announced on 19 April 2021 and tickets went on sale on 23 April. The tour was originally scheduled to take place between 15–24 October 2021 but was postponed due to logistical issues surrounding the COVID-19 pandemic. The tour began in Manchester on 5 April 2022 and Collins was joined by Stephen Bailey who assumed the role of presenter. The show featured Collins singing, looking back at her life and career and being interviewed by Bailey before taking questions from the audience. She performed in Glasgow, Southampton, London, Birmingham and Cardiff before the tour concluded in Newcastle on 14 April. In May 2022, Collins was set to take over the role of Matron "Mama" Morton in the UK tour of the musical Chicago. Following the announcement of her casting in March, producer David Ian said "[They] were completely stunned by [Collins'] audition for the role" describing her as "an undeniable force both on and off stage" and that "audiences across the country [were] in for a treat." Collins received criticism from several actors and theatre fans on social media who described her as a "stunt casting". Responding to critics, Collins said she "auditioned for the role and trained really hard" adding that she "didn't just get it because of [her alter ego] the GC".
==== Agitation of hydrophilic primer or adhesive during application ==== Besides having adequate dentinal moisture, agitation of the primers during application of two-step etch-and-rinse adhesives may be critical for optimal penetration into the demineralized collagen fibres. It also may aid the evaporation of residual water in the adhesive and hybrid layers, thus preventing nano leakage. In a clinical trial comparing the performance of Prime & Bond NT using no rubbing action, slight rubbing action and vigorous rubbing action in the restoration of NCCLs, 92.5% of restorations in vigorous rubbing action group were found to retain after 24 months of clinical service. For the other two groups, the retention rates of the restoration were slightly lower, at 82.5%.
Sources: en.wikipedia.org
The lyophilized powder is kept refrigerated at 2 to 8 degrees Celsius and protected from light. Reconstituted solutions should be used promptly. Freezing and thawing repeatedly is avoided.
Reversed-phase HPLC is the primary tool for purity, paired with mass spectrometry for identity. Amino acid analysis and peptide mapping add sequence confirmation. Several techniques are combined because no single test covers every attribute.
It lacks sulfur-containing residues, so oxidation is limited. Aspartate isomerization and slow hydrolysis are the main concerns. Solution stability is shorter than that of the lyophilized powder.
Reconstituted solutions are typically kept refrigerated at two to eight degrees Celsius when used within a short window, or frozen in aliquots for longer periods. Repeated freeze-thaw cycles are avoided because they can reduce recovery of intact peptide.